



CD33

Product: Anti-human Myeloid Monoclonal Antibodies

Description: Identification of human Monocytes (bright) and Granulocytes (dim) expressing the 67kDa M.W. surface antigen. CD33 is also found on CFU-mix, CFU-GM, CFU-Meg, a portion of BFU-E, myeloblasts, promyelocytes, myelocytes, metamyelocytes but not early precursors

Isotype: Mouse IgG1 kappa

Clone: FOS

Applications: Characterization of subtypes of leukemias and lymphomas; Studies of AIDS virus infection; Myeloid cell function studies; Analysis of hematopoietic maturation

Use: PBMC: Add 10 μ l of MAB/10⁶ PBMC in 100 μ l PBS. Mix gently and incubate for 15 minutes at 20^o to 8^oC. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. WHOLE BLOOD: Add 10 μ l of MAB/100 μ l of whole blood. Mix gently and incubate for 15 minutes at room temperature 20^oC. Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturer's instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.

Storage: Conjugated antibodies are supplied in PBS, 0.08% sodium azide and 0.2% protein carrier and should be stored at 4-8^oC. Conjugated antibodies should not be frozen. Reagents are stable for the period shown on the vial label when stored properly.

Ordering Information:	Form	Vial Size	Catalog #
	PE	100 Test	0334

REFERENCES:

1. Comparison of outcome, clinical, laboratory, and immunological features in 164 children and adults with T-ALL. Garand, R., Vannier, J.P., Bene, M.C., Faure, G., Favre, M., Bernard, A., Leukemia, 1990 No;4(11):739-44.
2. Immunologic Classification of Leukemia and Lymphoma. Foon, K.A., Todd, III, R.F. (1986)(1986) Blood ,68, 1
3. Surface marker expression in acute myeloid leukaemia at first relapse. Thomas X; Campos L; Archimbaud E; Shi ZH; Treille-Ritouet D; Anglaret B; Fiere D Br J Haematol 1992 May;81(1):40-4
4. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Robertson MJ; Soiffer RJ; Freedman AS; Rabinowe SL; Anderson KC; Ervin TJ; Murray C; Dear K; Griffin JD; Nadler LM; et al Blood 1992 May 1;79(9):2229-36
5. Expression of myeloid differentiation antigens in acute nonlymphocytic leukemia: increased concentration of CD33 antigen predicts poor outcome--a report from the Childrens Cancer Study Group. Dinndorf PA; Buckley JD; Nesbit ME; Lampkin BC; Piomelli S; Feig SA; Kersey JH; Hammond GD; Bernstein ID Med Pediatr Oncol 1992;20(3):192-200
6. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Bernstein ID; Singer JW; Smith FO; Andrews RG; Flowers DA; Petersens J; Steinmann L; Najfeld V; Savage D; Fruchtman S; et al Blood 1992 Apr 1;79(7):1811-6
7. The role of an anti-myeloperoxidase antibody in the diagnosis and classification of acute leukaemia: a comparison with light and electron microscopy cytochemistry. Buccheri V; Shetty V; Yoshida N; Morilla R; Matutes E; Catovsky D Br J Haematol 1992 Jan;80(1):62-8

For research use only. Not for use in human diagnostics or therapeutics.